Shanghai, China, 24 May 2021 —The Numen® Coil Embolization System (Numen®) and Numen FR® Coil Detachment System (Numen FR®), developed by Shanghai MicroPort NeuroTech Co., Ltd. (MicroPort® NeuroTech), recently received the CE Mark certification by the European Union. Previously, Numen® and Numen FR® were approved for marketing in China in 2020 and have been highly recognized by physicians and patients for their clinical performance.
The incidence rate of intracranial aneurysm is about 0.02-0.225‰ worldwide, and is higher among Asian populations at about 2.5%-3.0%. The possibility of aneurysm rupture increases over time, and intracranial aneurysms are known as “a ticking time bomb in the head” due to their high mortality and morbidity rate upon rupture.
The Numen® Coil Embolization System, with its stable baskets and dense packing, is primarily used in coil embolization procedures for the treatment of intracranial aneurysm. Numen® is available in different sizes, providing physicians a full range of embolization options for intracranial aneurysm and helping ensure the safety and efficacy of the procedures. The Numen FR® Coil Detachment System is for use in conjunction with the Numen® Coil Embolization system to assist in coil detachment.
“We always strive to provide a complete medical solution for patients with cerebral stroke”, said Zhiyong Xie, President of MicroPort® NeuroTech, “Our success in obtaining CE Mark certification for the Numen® products is an important recognition and a new starting point for us. MicroPort® NeuroTech will invest more resources in research and development to provide more quality and innovative solutions on cerebrovascular and neuro interventions for physicians and patients, both at home and abroad.”
About MicroPort® NeuroTech
MicroPort NeuroTech Co., Ltd. (MicroPort® NeuroTech) is a subsidiary of MicroPort Scientific Corporation (00853.HK). Founded in 2012, MicroPort® NeuroTech is a high-end medical device company focused on neuro-intervention and provides a full range of neuro-interventional products to treat brain disease.